UniProt functional annotation for Q84ZX5



	UniProt functional annotation for Q84ZX5

UniProt code: Q84ZX5.

Organism: Artemisia vulgaris (Mugwort).

Taxonomy: Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliopsida; eudicotyledons; Gunneridae; Pentapetalae; asterids; campanulids; Asterales; Asteraceae; Asteroideae; Anthemideae; Artemisiinae; Artemisia.

Subcellular location: Secreted {ECO:0000305|PubMed:12475905}.

Domain: Contains several extensin-like repeats in the C-terminal section. {ECO:0000305|PubMed:12475905}.

Ptm: The mature protein extracted from the plant exhibits an average rate of 76% of hydroxyprolines. {ECO:0000305|PubMed:12475905}.

Ptm: O-glycosylated. O-linkage of 3 galactoses plus 9-16 or 21-23 arabinose residues attached on one or two hydroxyprolines. {ECO:0000269|PubMed:12475905}.

Allergen: Causes an allergic reaction in human. Binds to IgE of mugwort pollen-sensitized patients (PubMed:12475905, PubMed:14510717, PubMed:20696401, PubMed:29220102, PubMed:30155917). Binds to IgE in 78% of the 113 Chinese patients tested (PubMed:29220102). Binds to IgE in 81% of the 240 Chinese patients tested. The patients from Southwestern China have significantly lower frequency of sensitization and lower IgE levels against this protein than the patients from Northern China. Patients allergic to multiple Artemisia allergens, including Art v 1, Art v 3 and Art an 7, have a higher risk of developing allergic asthma (PubMed:30155917). Post-translational modifications might be important in the formation of epitopes recognized by IgE antibodies from allergic patients (PubMed:12475905). {ECO:0000269|PubMed:12475905, ECO:0000269|PubMed:14510717, ECO:0000269|PubMed:20696401, ECO:0000269|PubMed:29220102, ECO:0000269|PubMed:30155917}.

Biotechnology: Post-translational modifications do not seem to influence T-cell recognition. Thus, recombinant non-glycosylated Art v 1 could be a starting template for engineering hypoallergenic vaccines for weed-pollen therapy (PubMed:12475905). Optimization of codon usage is required for effective genetic immunization against Art v 1 and should be considered in the development of vaccines for the treatment of allergy (PubMed:14510717). {ECO:0000269|PubMed:12475905, ECO:0000269|PubMed:14510717}.

Similarity: In the N-terminal section; belongs to the DEFL family. {ECO:0000305}.

Annotations taken from UniProtKB at the EBI.


Organism:		Artemisia vulgaris (Mugwort).
Taxonomy:		Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliopsida; eudicotyledons; Gunneridae; Pentapetalae; asterids; campanulids; Asterales; Asteraceae; Asteroideae; Anthemideae; Artemisiinae; Artemisia.


Subcellular location:		Secreted {ECO:0000305\|PubMed:12475905}.
Domain:		Contains several extensin-like repeats in the C-terminal section. {ECO:0000305\|PubMed:12475905}.
Ptm:		The mature protein extracted from the plant exhibits an average rate of 76% of hydroxyprolines. {ECO:0000305\|PubMed:12475905}.
Ptm:		O-glycosylated. O-linkage of 3 galactoses plus 9-16 or 21-23 arabinose residues attached on one or two hydroxyprolines. {ECO:0000269\|PubMed:12475905}.
Allergen:		Causes an allergic reaction in human. Binds to IgE of mugwort pollen-sensitized patients (PubMed:12475905, PubMed:14510717, PubMed:20696401, PubMed:29220102, PubMed:30155917). Binds to IgE in 78% of the 113 Chinese patients tested (PubMed:29220102). Binds to IgE in 81% of the 240 Chinese patients tested. The patients from Southwestern China have significantly lower frequency of sensitization and lower IgE levels against this protein than the patients from Northern China. Patients allergic to multiple Artemisia allergens, including Art v 1, Art v 3 and Art an 7, have a higher risk of developing allergic asthma (PubMed:30155917). Post-translational modifications might be important in the formation of epitopes recognized by IgE antibodies from allergic patients (PubMed:12475905). {ECO:0000269\|PubMed:12475905, ECO:0000269\|PubMed:14510717, ECO:0000269\|PubMed:20696401, ECO:0000269\|PubMed:29220102, ECO:0000269\|PubMed:30155917}.
Biotechnology:		Post-translational modifications do not seem to influence T-cell recognition. Thus, recombinant non-glycosylated Art v 1 could be a starting template for engineering hypoallergenic vaccines for weed-pollen therapy (PubMed:12475905). Optimization of codon usage is required for effective genetic immunization against Art v 1 and should be considered in the development of vaccines for the treatment of allergy (PubMed:14510717). {ECO:0000269\|PubMed:12475905, ECO:0000269\|PubMed:14510717}.
Similarity:		In the N-terminal section; belongs to the DEFL family. {ECO:0000305}.